文献速递物质与行为成瘾精神分裂症与精神病性障碍

国际大麻政策与使用、使用障碍及其他精神障碍的关联

International cannabis policies and their association with cannabis use, cannabis use disorder, and other psychiatric disorders.
PubMed 文献 · Lancet Psychiatry · 2026-01-01

商业化合法市场与非医疗使用增加及使用障碍患病率上升相关;政策变化与精神病性障碍患病率或发病率无一致关联,但商业化合法化与精神病住院增加相关。

要点

  • 商业化合法市场与大麻使用及使用障碍患病率上升相关。
  • 政策变化与精神病性障碍患病率或发病率无一致关联。
  • 商业化合法化与精神病住院及共病使用障碍的精神病住院增加相关。

核心结论

  • 商业化合法市场与大麻使用和使用障碍患病率增加相关,并伴随大麻效力上升。
  • 政策变化与精神病性障碍患病率或发病率无一致关联,但商业化合法化与精神病住院增加相关。
  • 限制商业化的政策与使用或精神障碍的关联较弱,但需长期评估。

主要发现

  • 加拿大和美国的非医疗用途商业化合法市场与大麻使用和使用障碍患病率增加相关,且合法化后大麻效力上升。
  • 商业化合法化与精神病住院增加相关,也与共病使用障碍的精神病性障碍住院增加相关。
  • 监管不力的医疗大麻合法获取在缺乏疗效和安全性数据时可能增加伤害风险。
  • 欧洲、非洲、大洋洲和亚洲的非医疗大麻非犯罪化与使用或精神障碍的关联证据较少。

临床怎么用

  • 评估大麻政策时需关注商业化程度对使用和精神障碍住院风险的潜在影响。
  • 医疗大麻合法获取应基于疗效和安全性数据,避免监管不力增加伤害风险。

局限性

  • 限制商业化的政策与使用或精神障碍关联较弱,但需长期评估。
  • 非犯罪化与使用或精神障碍的关联证据较少。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Cannabis policies vary from strict prohibition to commercialised legalisation and are rapidly evolving worldwide. Here, we reviewed evidence for associations between international cannabis policy changes from 2000-25 and cannabis use, cannabis use disorder, and other psychiatric disorders. Commercialised legal markets for non-medical use in Canada and the USA were associated with increased prevalence of cannabis use and cannabis use disorder in adults and increases in cannabis potency since legalisation. There was no consistent evidence for associations between policy change and the prevalence or incidence of psychotic disorders. Commercialised legalisation was associated with an increase in hospital admissions for psychosis, and for psychotic disorders comorbid with cannabis use disorder. Poorly regulated legal access to medical cannabis, in the absence of efficacy and safety data, could increase risk of harm. Policies that limit commercialisation, such as strictly regulated legalisation of medical or non-medical supply, were not as strongly associated with cannabis use or psychiatric disorders, but long-term evaluation is needed. There was little evidence that decriminalisation of non-medical cannabis in Europe, Africa, Oceania, and Asia was associated with cannabis use or psychiatric disorders.

来源:Lancet Psychiatry,查看原文。版权归原作者所有。

引用

  1. Freeman TP, Thorne RL, Wadsworth E, et al. International cannabis policies and their association with cannabis use, cannabis use disorder, and other psychiatric disorders. Lancet Psychiatry. 2026. PMID: 42309107. doi:10.1016/S2215-0366(26)00087-8

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。